文献速递外周动脉疾病

BEST-CLI 试验中因慢性肢体威胁性缺血行开放或血管内血运重建后的围手术期并发症

Perioperative complications following open or endovascular revascularization for chronic limb-threatening ischemia in the BEST-CLI Trial.
PubMed 文献 · J Vasc Surg · 2023-06-14

BEST-CLI 是一项前瞻性随机试验,比较开放手术(OPEN)与血管内(ENDO)血运重建策略。队列1(有充足单段大隐静脉)1367例,队列2(无单段大隐静脉)379例。按方案分析显示,两队列30天主要不良心血管事件在OPEN与ENDO间均无显著差异,作者认为围手术期并发症风险不应成为决定血运重建策略的阻碍因素。

要点

  • 队列1的30天MACE:OPEN 4.7% vs ENDO 3.13%(P=0.14);队列2:OPEN 4.28% vs ENDO 1.05%(P=0.15)。
  • 风险校正后30天MACE无差异:队列1 HR 1.5(95%CI 0.85-2.64,P=0.16),队列2 HR 2.17(95%CI 0.48-9.88,P=0.31)。
  • 队列1任何非严重不良事件OPEN 23.4% vs ENDO 17.9%(P=0.013);队列2 OPEN 21.8% vs ENDO 19.9%(P=0.7)。

核心结论

  • 在BEST-CLI中,被认为适合开放下肢旁路手术的CLTI患者,接受OPEN或ENDO血运重建后的围手术期并发症相似。
  • 作者认为,对此类患者,围手术期并发症风险的担忧不应成为决定血运重建策略的阻碍因素。
  • 作者认为,恢复灌注的有效性和患者偏好等其他因素更为相关。

研究设计与样本

  • BEST-CLI为前瞻性随机试验,比较开放(OPEN)与血管内(ENDO)血运重建策略。
  • 研究两个平行队列:队列1为有充足单段大隐静脉(SSGSV)的患者,队列2为无SSGSV的患者。
  • 队列1共1367例(OPEN 662例,ENDO 705例),队列2共379例(OPEN 188例,ENDO 191例)。
  • 评估术后30天主要不良心血管事件(MACE,复合心肌梗死、卒中、死亡)、非严重不良事件(non-SAEs)和严重不良事件(SAEs)。
  • 采用按方案分析(接受干预且未交叉),并进行风险校正分析。

主要发现

  • 队列1的30天死亡率:OPEN 1.8% vs ENDO 1.3%;队列2:OPEN 2.7% vs ENDO 0%。
  • 队列1的MACE:OPEN 4.7% vs ENDO 3.13%(P=0.14);队列2:OPEN 4.28% vs ENDO 1.05%(P=0.15)。
  • 风险校正后30天MACE无差异:队列1 HR 1.5(95%CI 0.85-2.64,P=0.16),队列2 HR 2.17(95%CI 0.48-9.88,P=0.31)。
  • 急性肾衰竭发生率相似:队列1 OPEN 3.6% vs ENDO 2.1%(HR 1.6,95%CI 0.85-3.12,P=0.14),队列2 OPEN 4.2% vs ENDO 1.6%(HR 2.86,95%CI 0.75-10.8,P=0.12)。
  • 静脉血栓栓塞发生率总体低且组间相似:队列1 OPEN 0.9% vs ENDO 0.4%,队列2 OPEN 0.5% vs ENDO 0%。

临床怎么用

  • 作者认为,对于适合开放下肢旁路手术的CLTI患者,围手术期并发症风险的担忧不应成为决定血运重建策略的阻碍因素。
  • 作者认为,恢复灌注的有效性和患者偏好等其他因素更为相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Anticipated perioperative morbidity is an important factor for choosing a revascularization method for chronic limb-threatening ischemia (CLTI). Our goal was to assess systemic perioperative complications of patients treated with surgical and endovascular revascularization in the Best Endovascular vs Best Surgical Therapy in Patients with CLTI (BEST-CLI) trial. METHODS: BEST-CLI was a prospective randomized trial comparing open (OPEN) and endovascular (ENDO) revascularization strategies for patients with CLTI. Two parallel cohorts were studied: Cohort 1 included patients with adequate single-segment great saphenous vein (SSGSV), whereas Cohort 2 included those without SSGSV. Data were queried for major adverse cardiovascular events (MACE-composite myocardial infarction, stroke, death), non-serious (non-SAEs) and serious adverse events (SAEs) (criteria-death/life-threatening/requiring hospitalization or prolongation of hospitalization/significant disability/incapacitation/affecting subject safety in trial) 30 days after the procedure. Per protocol analysis was used (intervention received without crossover), and risk-adjusted analysis was performed. RESULTS: There were 1367 patients (662 OPEN, 705 ENDO) in Cohort 1 and 379 patients (188 OPEN, 191 ENDO) in Cohort 2. Thirty-day mortality in Cohort 1 was 1.5% (OPEN 1.8%; ENDO 1.3%) and in Cohort 2 was 1.3% (2.7% OPEN; 0% ENDO). MACE in Cohort 1 was 4.7% for OPEN vs 3.13% for ENDO (P = .14), and in Cohort 2, was 4.28% for OPEN and 1.05% for ENDO (P = .15). On risk-adjusted analysis, there was no difference in 30-day MACE for OPEN vs ENDO for Cohort 1 (hazard ratio [HR] 1.5; 95% confidence interval [CI], 0.85-2.64; P = .16) or Cohort 2 (HR, 2.17; 95% CI, 0.48-9.88; P = .31). The incidence of acute renal failure was similar across interventions; in Cohort 1 it was 3.6% for OPEN vs 2.1% for ENDO (HR, 1.6; 95% CI, 0.85-3.12; P = .14), and in Cohort 2, it was 4.2% OPEN vs 1.6% ENDO (HR, 2.86; 95% CI, 0.75-10.8; P = .12). The occurrence of venous thromboembolism was low overall and was similar between groups in Cohort 1 (OPEN 0.9%; ENDO 0.4%) and Cohort 2 (OPEN 0.5%; ENDO 0%). Rates of any non-SAEs in Cohort 1 were 23.4% in OPEN and 17.9% in ENDO (P = .013); in Cohort 2, they were 21.8% for OPEN and 19.9% for ENDO (P = .7). Rates for any SAEs in Cohort 1 were 35.3% for OPEN and 31.6% for ENDO (P = .15); in Cohort 2, they were 25.5% for OPEN and 23.6% for ENDO (P = .72). The most common types of non-SAEs and SAEs were infection, procedural complications, and cardiovascular events. CONCLUSIONS: In BEST-CLI, patients with CLTI who were deemed suitable candidates for open lower extremity bypass surgery had similar peri-procedural complications following either OPEN or ENDO revascularization: In such patients, concern about risk of peri-procedure complications should not be a deterrent in deciding revascularization strategy. Rather, other factors, including effectiveness in restoring perfusion and patient preference, are more relevant.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Siracuse JJ, Farber A, Menard MT, et al. Perioperative complications following open or endovascular revascularization for chronic limb-threatening ischemia in the BEST-CLI Trial. J Vasc Surg. 2023. PMID: 37318428. doi:10.1016/j.jvs.2023.05.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。